Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2026)

Akebia Therapeutics (AKBA) has 11 years of Current Deferred Revenue data on file, last reported at $4.5 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 262.29% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a 262.29% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, changed N/A from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $4.5 million, up from $2.7 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for AKBA reached as high as $66.3 million in Q3 2022 and fell as low as $1.2 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $30.5 million across 5 years, with a median of $43.3 million in 2023.
• Across the five-year window, Current Deferred Revenue tumbled 97.18% in 2025 and soared 262.29% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $47.0 million in 2022, then declined by 7.95% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024, then plunged by 93.81% to $2.7 million in 2025, then soared by 67.7% to $4.5 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $4.5 million in Q1 2026, $2.7 million in Q4 2025, and $3.9 million in Q3 2025.